Oryzon Genomics S.A.
Oryzon Genomics S.A. (ORYZF) Company Profile & Overview
Explore Oryzon Genomics S.A.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Oryzon Genomics S.A. (ORYZF) Company Profile & Overview
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.